BioSpace News Archive

CN Bio, a leading Organ-on-a-Chip company that designs and manufactures single-and multi-organ microphysiological systems, has received the ‘Most Impactful Industry Collaboration of the Year’ at the 2023 OBN Awards.

Vertex Pharmaceuticals Incorporated announced that the European Commission has granted approval for the label expansion of KAFTRIO® in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.

Everest Medicines announced that China’s National Medical Products Administration has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy in adults at risk of disease progression.